Background : Numerous studies have outlined the cellular pleiotropic effects of
erythropoietin (EPO) and their role in the prevention of ischemic-reperfusion lesion such as
after acute ischemic injury of the brain or the heart. However, most of these studies were
carried out in animal models and no definitive proof exists today to demonstrate that EPO has
similar beneficial effects in human pathology.
Purpose : The aim of the study is to demonstrate that in humans, EPO can protect against
ischemic-reperfusion lesions in a model of ischemia i.e. kidney transplantation.